Fagron NV (EBR:FAGR)
20.90
+0.15 (0.72%)
At close: Dec 5, 2025
Fagron NV Revenue
Fagron NV had revenue of 476.13M EUR in the half year ending June 30, 2025, with 28.14% growth. This brings the company's revenue in the last twelve months to 918.75M, up 11.94% year-over-year. In the year 2024, Fagron NV had annual revenue of 871.96M with 14.28% growth.
Revenue (ttm)
918.75M
Revenue Growth
+11.94%
P/S Ratio
1.67
Revenue / Employee
230.32K
Employees
3,828
Market Cap
1.53B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 871.96M | 108.97M | 14.28% |
| Dec 31, 2023 | 762.99M | 79.11M | 11.57% |
| Dec 31, 2022 | 683.88M | 110.07M | 19.18% |
| Dec 31, 2021 | 573.81M | 17.84M | 3.21% |
| Dec 31, 2020 | 555.97M | 21.28M | 3.98% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| argenx SE | 3.14B |
| UCB SA | 6.85B |
| Financière de Tubize | 13.26K |
| Ion Beam Applications | 585.76M |
| Onward Medical | 2.72M |
| Hyloris Pharmaceuticals | 8.46M |
| Nyxoah | 5.64M |
| Sequana Medical NV | 105.50K |
Fagron NV News
- 2 days ago - Pharma 5.0 delivers personalized treatment using AI, says Fagron CEO - CNBC
- 12 days ago - Fagron Announces Acquisitions Of Amara And Magilab - Nasdaq
- 4 weeks ago - Half Year 2025 Fagron NV Earnings Call Transcript - GuruFocus
- 2 months ago - Fagron NV (ARSUF) Q3 2025 Sales Call Transcript - Seeking Alpha
- 2 months ago - Fagron NV (ARSUF) Q3 2025 Sales/ Trading Statement Call - Slideshow - Seeking Alpha
- 2 months ago - Fagron reports solid third quarter performance with 6.4% revenue growth and confirms full year outlook - GlobeNewsWire
- 6 months ago - Fagron increases share capital through exercise subscription rights - GlobeNewsWire
- 7 months ago - Fagron: Recent Capital Markets Day Confirms Upside Potential - Seeking Alpha